There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
Ann: 2023 Full Year Results Investor Presentation, page-35
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.52 |
Change
-0.130(2.80%) |
Mkt cap ! $384.9M | |||
| Open | High | Low | Value | Volume |
| $4.62 | $4.62 | $4.50 | $256.8K | 56.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1429 | $4.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.53 | 502 | 13 |
View Market Depth
| Last trade - 10.54am 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.52 |
Change
-0.130 ( 2.03 %) |
||||
| Open | High | Low | Volume | ||
| $4.60 | $4.60 | $4.51 | 4697 | ||
| Last updated 11.10am 17/06/2024 ? | |||||
| MYX (ASX) Chart |
